Hutchmed $HCM
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS11
PHASE 3 / 2-38
RECRUITING8
READOUTS ≤12 MONTHS0
READOUT SLIPPED >6 MO57%
Delay Index: of 7 active trials registered more than a year ago, 4 have moved their primary completion (readout) date by more than 6 months since first registration (median +9.0 months). See all sponsors →
Open Hutchmed on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| wAIHA NCT05535933 |
P2/3 | Active, not recruiting | Warm Antibody Autoimmune Hemolytic Anemia | 111 | 2025-11-25 (-9 mo) |
| HMPL-760 NCT07409428 |
P3 | Recruiting | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | 240 | 2028-04-30 |
| SANOVO NCT05009836 |
P3 | Active, not recruiting | Non-small Cell Lung Cancer | 412 | 2028-05-30 (+42 mo) |
| Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine NCT06361888 |
P2/3 | Recruiting | Metastatic Pancreatic Cancer | 502 | 2028-05-31 (+9 mo) |
| HMPL-453 NCT04353375 |
P2/3 | Recruiting | Advanced Intrahepatic Cholangiocarcinoma; Solid Tumor, Adult | 235 | 2028-06-30 (+66 mo) |
| HMPL-A251 NCT07228247 |
P1/2 | Recruiting | Solid Tumors, Adult | 147 | 2028-11-30 |
| HMPL-306 Regimen NCT06387069 |
P3 | Recruiting | Acute Myeloid Leukemia | 316 | 2028-12-31 (+19 mo) |
| HMPL-A580 NCT07396584 |
P1/2 | Recruiting | Solid Tumors, Adult | 186 | 2028-12-31 |
| fruquintinib NCT06584032 |
P3 | Recruiting | Advanced Endometrial Cancer | 412 | 2029-01-08 |
| HMPL-A830 NCT07718581 |
P1/2 | Recruiting | Solid Tumor, Adult | 147 | 2029-05-23 |
| HMPL-306 tablet NCT07912398 |
P3 | Not yet recruiting | Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation | 210 | 2032-03 |